In vitro synergistic effects of zoledronic acid and calcium on viability of human epithelial cells

被引:8
作者
Arai, N. [1 ]
Inoue, S. [1 ]
Tomihara, K. [1 ]
Tsuno, H. [1 ]
Noguchi, M. [1 ]
机构
[1] Toyama Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med & Pharmaceut Sci Res, Toyama 9300194, Japan
关键词
bisphosphonate; osteonecrosis; zoledronate; oral mucosa; keratinocytes; serum; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; NITROGEN-CONTAINING BISPHOSPHONATES; CANCER-PATIENTS; JAWS; INHIBITION; PHARMACOKINETICS; PHARMACODYNAMICS; ANTITUMOR; GROWTH; MODEL;
D O I
10.1111/j.1601-0825.2012.01971.x
中图分类号
R78 [口腔科学];
学科分类号
100302 [口腔临床医学];
摘要
OBJECTIVE: Bisphosphonate-related osteonecrosis of the jaw is a common complication with defective wound healing of oral mucosa and frequently occurs in patients receiving zoledronic acid (ZA). The aim of this in vitro study was to investigate whether ZA has a cytotoxic effect at clinically relevant concentrations on epithelial cells when calcium conditions are altered. METHODS: HaCaT human keratinocyte cells were treated with ZA in the presence of various concentrations of calcium. The concentrations of ZA included submicromolar ones, which are comparable with those found in the plasma of patients. Cell viability and apoptosis were assessed using MTT assay and annexin V flow cytometry. RESULTS: Under standard culture conditions, cell growth was inhibited at 1 mu M of ZA or above, but was unaffected by lower concentrations. However, when calcium concentrations were moderately increased, cell viability was decreased and apoptosis was induced at 0.2-0.3 mu M of ZA. Moreover, a 50% reduction in serum in the hypercalcemic medium resulted in a significant decrease in cell viability at a much lower concentration (0.05 mu M). CONCLUSION: These results suggest that clinically relevant concentrations of ZA, which alone have little effects, can be toxic to the epithelial cells depending on the conditions of extracellular calcium. Oral Diseases (2013) 19, 200-205
引用
收藏
页码:200 / 205
页数:6
相关论文
共 32 条
[1]
Adverse Effects of Bisphosphonates [J].
Abrahamsen, Bo .
CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) :421-435
[2]
Is Zoledronate Toxic to Human Periodontal Fibroblasts? [J].
Agis, H. ;
Blei, J. ;
Watzek, G. ;
Gruber, R. .
JOURNAL OF DENTAL RESEARCH, 2010, 89 (01) :40-45
[3]
In vivo effects of zoledronic acid on oral mucosal epithelial cells [J].
Allam, E. ;
Allen, M. R. ;
Chu, T-M ;
Ghoneima, A. ;
Windsor, L. Jack .
ORAL DISEASES, 2011, 17 (03) :291-297
[4]
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].
Chen, TL ;
Berenson, J ;
Vescio, R ;
Swift, R ;
Gilchick, A ;
Goodin, S ;
LoRusso, P ;
Ma, PM ;
Ravera, C ;
Deckert, F ;
Schran, H ;
Seaman, J ;
Skerjanec, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236
[5]
Clezardin P., 2009, IBMS BONEKEY, V6, P210, DOI [10.1138/20090381, DOI 10.1138/20090381]
[6]
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line [J].
Di Salvatore, M. ;
Orlandi, A. ;
Bagala, C. ;
Quirino, M. ;
Cassano, A. ;
Astone, A. ;
Barone, C. .
CELL PROLIFERATION, 2011, 44 (02) :139-146
[7]
Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
[8]
Fournier P, 2002, CANCER RES, V62, P6538
[9]
Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis [J].
Hansen, T ;
Kunkel, M ;
Weber, A ;
Kirkpatrick, CJ .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2006, 35 (03) :155-160
[10]
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells [J].
Journe, Fabrice ;
Kheddoumi, Naima ;
Chaboteaux, Carole ;
Duvillier, Hugues ;
Laurent, Guy ;
Body, Jean-Jacques .
BREAST CANCER RESEARCH, 2008, 10 (01)